NOVN has been the subject of several other reports. Zacks Investment Research downgraded shares of Novan from a “hold” rating to a “sell” rating in a research note on Saturday, May 11th. JMP Securities downgraded shares of Novan from an “outperform” rating to a “market perform” rating in a research note on Friday, March 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Novan has a consensus rating of “Hold” and an average target price of $4.33.
Shares of NASDAQ NOVN opened at $2.25 on Thursday. Novan has a twelve month low of $0.65 and a twelve month high of $3.25.
A number of institutional investors and hedge funds have recently bought and sold shares of NOVN. Bank of New York Mellon Corp bought a new stake in Novan in the fourth quarter valued at $25,000. RMB Capital Management LLC increased its stake in Novan by 45.5% in the fourth quarter. RMB Capital Management LLC now owns 32,000 shares of the company’s stock valued at $27,000 after purchasing an additional 10,000 shares in the last quarter. Deutsche Bank AG increased its stake in Novan by 4,462.7% in the fourth quarter. Deutsche Bank AG now owns 47,863 shares of the company’s stock valued at $39,000 after purchasing an additional 46,814 shares in the last quarter. Prospera Financial Services Inc increased its stake in Novan by 44.3% in the first quarter. Prospera Financial Services Inc now owns 87,552 shares of the company’s stock valued at $79,000 after purchasing an additional 26,860 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Novan by 52.0% in the third quarter. Renaissance Technologies LLC now owns 89,700 shares of the company’s stock valued at $250,000 after purchasing an additional 30,700 shares in the last quarter. 6.35% of the stock is owned by hedge funds and other institutional investors.
Novan Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: Quiet Period Expirations Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.